By Fineline Cube 
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic product HWS116. The study will evaluate the drug in patients with advanced solid tumors.
Development Investment and Innovation
The development of HWS116 has cost Humanwell RMB 38 million (USD 5.2 million), underscoring the company’s commitment to innovation in oncology treatment. Currently, there are no comparable products approved in China, positioning HWS116 as a potential groundbreaking therapy for advanced solid tumors.-Fineline Info & Tech